Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Germline variability and tumor expression level of ribosomal protein gene RPL28 are associated with survival of metastatic colorectal cancer patients.

Labriet A, Lévesque É, Cecchin E, De Mattia E, Villeneuve L, Rouleau M, Jonker D, Couture F, Simonyan D, Allain EP, Buonadonna A, D'Andrea M, Toffoli G, Guillemette C.

Sci Rep. 2019 Sep 10;9(1):13008. doi: 10.1038/s41598-019-49477-3.

2.

Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.

De Mattia E, Cecchin E, Guardascione M, Foltran L, Di Raimo T, Angelini F, D'Andrea M, Toffoli G.

World J Gastroenterol. 2019 Aug 7;25(29):3870-3896. doi: 10.3748/wjg.v25.i29.3870. Review.

3.

The prognostic value of spirometric tests in Amyotrophic Lateral Sclerosis patients.

Pirola A, De Mattia E, Lizio A, Sannicolò G, Carraro E, Rao F, Sansone V, Lunetta C.

Clin Neurol Neurosurg. 2019 Sep;184:105456. doi: 10.1016/j.clineuro.2019.105456. Epub 2019 Jul 29.

PMID:
31382080
4.

Genetic markers of the host to predict the efficacy of colorectal cancer targeted therapy.

De Mattia E, Bignucolo A, Toffoli G, Cecchin E.

Curr Med Chem. 2019 Jul 12. doi: 10.2174/0929867326666190712151417. [Epub ahead of print]

PMID:
31298142
5.

New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) Approach.

Garziera M, Roncato R, Montico M, De Mattia E, Gagno S, Poletto E, Scalone S, Canzonieri V, Giorda G, Sorio R, Cecchin E, Toffoli G.

Cells. 2019 Jun 14;8(6). pii: E584. doi: 10.3390/cells8060584.

6.

rs4143815-PDL1, a New Potential Immunogenetic Biomarker of Biochemical Recurrence in Locally Advanced Prostate Cancer after Radiotherapy.

Zanusso C, Dreussi E, Bortolus R, Romualdi C, Gagno S, De Mattia E, Romanato L, Sartor F, Quartuccio L, Cecchin E, Toffoli G.

Int J Mol Sci. 2019 Apr 27;20(9). pii: E2082. doi: 10.3390/ijms20092082.

7.

FARMAPRICE: A Pharmacogenetic Clinical Decision Support System for Precise and Cost-Effective Therapy.

Roncato R, Dal Cin L, Mezzalira S, Comello F, De Mattia E, Bignucolo A, Giollo L, D'Errico S, Gulotta A, Emili L, Carbone V, Guardascione M, Foltran L, Toffoli G, Cecchin E.

Genes (Basel). 2019 Apr 4;10(4). pii: E276. doi: 10.3390/genes10040276.

8.

Consensus-based care recommendations for adults with myotonic dystrophy type 1.

Ashizawa T, Gagnon C, Groh WJ, Gutmann L, Johnson NE, Meola G, Moxley R 3rd, Pandya S, Rogers MT, Simpson E, Angeard N, Bassez G, Berggren KN, Bhakta D, Bozzali M, Broderick A, Byrne JLB, Campbell C, Cup E, Day JW, De Mattia E, Duboc D, Duong T, Eichinger K, Ekstrom AB, van Engelen B, Esparis B, Eymard B, Ferschl M, Gadalla SM, Gallais B, Goodglick T, Heatwole C, Hilbert J, Holland V, Kierkegaard M, Koopman WJ, Lane K, Maas D, Mankodi A, Mathews KD, Monckton DG, Moser D, Nazarian S, Nguyen L, Nopoulos P, Petty R, Phetteplace J, Puymirat J, Raman S, Richer L, Roma E, Sampson J, Sansone V, Schoser B, Sterling L, Statland J, Subramony SH, Tian C, Trujillo C, Tomaselli G, Turner C, Venance S, Verma A, White M, Winblad S.

Neurol Clin Pract. 2018 Dec;8(6):507-520. doi: 10.1212/CPJ.0000000000000531. Review.

9.

The Genotype for DPYD Risk Variants in Patients With Colorectal Cancer and the Related Toxicity Management Costs in Clinical Practice.

Toffoli G, Innocenti F, Polesel J, De Mattia E, Sartor F, Dalle Fratte C, Ecca F, Dreussi E, Palazzari E, Guardascione M, Buonadonna A, Foltran L, Garziera M, Bignucolo A, Nobili S, Mini E, Favaretto A, Berretta M, D'Andrea M, De Paoli A, Roncato R, Cecchin E.

Clin Pharmacol Ther. 2019 Apr;105(4):994-1002. doi: 10.1002/cpt.1257. Epub 2018 Nov 22.

PMID:
30339275
10.

A Clinical-Genetic Score to Identify Surgically Resected Colorectal Cancer Patients Benefiting From an Adjuvant Fluoropyrimidine-Based Therapy.

De Mattia E, Dreussi E, Montico M, Gagno S, Zanusso C, Quartuccio L, De Vita S, Guardascione M, Buonadonna A, D'Andrea M, Pella N, Favaretto A, Mini E, Nobili S, Romanato L, Cecchin E, Toffoli G.

Front Pharmacol. 2018 Oct 4;9:1101. doi: 10.3389/fphar.2018.01101. eCollection 2018.

11.

Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation.

Cecchin E, De Mattia E, Ecca F, Toffoli G.

Drug Resist Updat. 2018 Jul;39:18-40. doi: 10.1016/j.drup.2018.07.001. Epub 2018 Jul 10. Review.

PMID:
30075835
12.

Identification of Novel Somatic TP53 Mutations in Patients with High-Grade Serous Ovarian Cancer (HGSOC) Using Next-Generation Sequencing (NGS).

Garziera M, Cecchin E, Canzonieri V, Sorio R, Giorda G, Scalone S, De Mattia E, Roncato R, Gagno S, Poletto E, Romanato L, Sartor F, Polesel J, Toffoli G.

Int J Mol Sci. 2018 May 18;19(5). pii: E1510. doi: 10.3390/ijms19051510.

13.

Passive Versus Active Circuit During Invasive Mechanical Ventilation in Subjects With Amyotrophic Lateral Sclerosis.

De Mattia E, Falcier E, Lizio A, Lunetta C, Sansone VA, Barbarito N, Garabelli B, Iatomasi M, Roma E, Rao F, Carlucci A.

Respir Care. 2018 Sep;63(9):1132-1138. doi: 10.4187/respcare.05866. Epub 2018 May 15.

14.

Association of STAT-3 rs1053004 and VDR rs11574077 With FOLFIRI-Related Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients.

De Mattia E, Cecchin E, Montico M, Labriet A, Guillemette C, Dreussi E, Roncato R, Bignucolo A, Buonadonna A, D'Andrea M, Coppola L, Lonardi S, Lévesque E, Jonker D, Couture F, Toffoli G.

Front Pharmacol. 2018 Apr 13;9:367. doi: 10.3389/fphar.2018.00367. eCollection 2018.

15.

Impact of an early respiratory care programme with non-invasive ventilation adaptation in patients with amyotrophic lateral sclerosis.

Vitacca M, Montini A, Lunetta C, Banfi P, Bertella E, De Mattia E, Lizio A, Volpato E, Lax A, Morini R, Paneroni M; ALS RESPILOM Study Group.

Eur J Neurol. 2018 Mar;25(3):556-e33. doi: 10.1111/ene.13547. Epub 2018 Jan 29.

PMID:
29266547
16.

Genetic biomarkers for hepatocellular cancer risk in a caucasian population.

De Mattia E, Cecchin E, Polesel J, Bignucolo A, Roncato R, Lupo F, Crovatto M, Buonadonna A, Tiribelli C, Toffoli G.

World J Gastroenterol. 2017 Sep 28;23(36):6674-6684. doi: 10.3748/wjg.v23.i36.6674.

17.

Improved Progression-Free Survival in Irinotecan-Treated Metastatic Colorectal Cancer Patients Carrying the HNF1A Coding Variant p.I27L.

Labriet A, De Mattia E, Cecchin E, Lévesque É, Jonker D, Couture F, Buonadonna A, D'Andrea M, Villeneuve L, Toffoli G, Guillemette C.

Front Pharmacol. 2017 Oct 10;8:712. doi: 10.3389/fphar.2017.00712. eCollection 2017.

18.

Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment.

Bignucolo A, De Mattia E, Cecchin E, Roncato R, Toffoli G.

Int J Mol Sci. 2017 Jul 14;18(7). pii: E1522. doi: 10.3390/ijms18071522. Review.

19.

HLA-G 3'UTR Polymorphisms Predict Drug-Induced G3-4 Toxicity Related to Folinic Acid/5-Fluorouracil/Oxaliplatin (FOLFOX4) Chemotherapy in Non-Metastatic Colorectal Cancer.

Garziera M, Virdone S, De Mattia E, Scarabel L, Cecchin E, Polesel J, D'Andrea M, Pella N, Buonadonna A, Favaretto A, Toffoli G.

Int J Mol Sci. 2017 Jun 27;18(7). pii: E1366. doi: 10.3390/ijms18071366.

20.

Use of the Intermittent Abdominal Pressure Ventilation to guarantee speech in a tracheostomized Amyotrophic Lateral Sclerosis patient.

De Mattia E, Iatomasi M, Garabelli B, Lunetta C, Sansone VA, Rao F.

Rev Port Pneumol (2006). 2017 Jul - Aug;23(4):236-239. doi: 10.1016/j.rppnen.2017.03.002. Epub 2017 May 31. No abstract available.

21.

UGT1A polymorphisms as genetic biomarkers for hepatocellular carcinoma risk in Caucasian population.

De Mattia E, Cecchin E, Polesel J, Lupo F, Tiribelli C, Crovatto M, Buonadonna A, Toffoli G.

Liver Int. 2017 Sep;37(9):1345-1353. doi: 10.1111/liv.13411. Epub 2017 Apr 6.

PMID:
28294511
22.

Obesity paradox in chronic obstructive pulmonary disease: A result of airflow obstruction over-grading?

Barbarito N, De Mattia E.

Respir Med. 2017 May;126:133. doi: 10.1016/j.rmed.2016.08.012. Epub 2016 Oct 18. No abstract available.

23.

Cost Evaluation of Irinotecan-Related Toxicities Associated With the UGT1A1*28 Patient Genotype.

Roncato R, Cecchin E, Montico M, De Mattia E, Giodini L, Buonadonna A, Solfrini V, Innocenti F, Toffoli G.

Clin Pharmacol Ther. 2017 Jul;102(1):123-130. doi: 10.1002/cpt.615. Epub 2017 Mar 20.

PMID:
28074472
24.

BNC2 is a putative tumor suppressor gene in high-grade serous ovarian carcinoma and impacts cell survival after oxidative stress.

Cesaratto L, Grisard E, Coan M, Zandonà L, De Mattia E, Poletto E, Cecchin E, Puglisi F, Canzonieri V, Mucignat MT, Zucchetto A, Stocco G, Colombatti A, Nicoloso MS, Spizzo R.

Cell Death Dis. 2016 Dec 22;7(12):e2526. doi: 10.1038/cddis.2016.448. No abstract available.

25.

BNC2 is a putative tumor suppressor gene in high-grade serous ovarian carcinoma and impacts cell survival after oxidative stress.

Cesaratto L, Grisard E, Coan M, Zandonà L, De Mattia E, Poletto E, Cecchin E, Puglisi F, Canzonieri V, Mucignat MT, Zucchetto A, Stocco G, Colombatti A, Nicoloso MS, Spizzo R.

Cell Death Dis. 2016 Sep 22;7(9):e2374. doi: 10.1038/cddis.2016.278. Erratum in: Cell Death Dis. 2016 Dec 22;7(12 ):e2526.

26.

Pharmacogenetics Biomarkers and Their Specific Role in Neoadjuvant Chemoradiotherapy Treatments: An Exploratory Study on Rectal Cancer Patients.

Dreussi E, Cecchin E, Polesel J, Canzonieri V, Agostini M, Boso C, Belluco C, Buonadonna A, Lonardi S, Bergamo F, Gagno S, De Mattia E, Pucciarelli S, De Paoli A, Toffoli G.

Int J Mol Sci. 2016 Sep 5;17(9). pii: E1482. doi: 10.3390/ijms17091482.

27.

Pregnane X receptor, constitutive androstane receptor and hepatocyte nuclear factors as emerging players in cancer precision medicine.

De Mattia E, Cecchin E, Roncato R, Toffoli G.

Pharmacogenomics. 2016 Sep;17(14):1547-71. doi: 10.2217/pgs-2016-0095. Epub 2016 Aug 26. Review.

PMID:
27561454
28.

Predictive role of microRNA-related genetic polymorphisms in the pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients.

Dreussi E, Pucciarelli S, De Paoli A, Polesel J, Canzonieri V, Agostini M, Friso ML, Belluco C, Buonadonna A, Lonardi S, Zanusso C, De Mattia E, Toffoli G, Cecchin E.

Oncotarget. 2016 Apr 12;7(15):19781-93. doi: 10.18632/oncotarget.7757.

29.

Nuclear receptors and drug metabolism for the personalization of cancer therapy.

Cecchin E, De Mattia E, Toffoli G.

Expert Opin Drug Metab Toxicol. 2016;12(3):291-306. doi: 10.1517/17425255.2016.1141196. Epub 2016 Feb 1. Review.

PMID:
26789519
30.

HLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment.

Garziera M, Bidoli E, Cecchin E, Mini E, Nobili S, Lonardi S, Buonadonna A, Errante D, Pella N, D'Andrea M, De Marchi F, De Paoli A, Zanusso C, De Mattia E, Tassi R, Toffoli G.

PLoS One. 2015 Dec 3;10(12):e0144000. doi: 10.1371/journal.pone.0144000. eCollection 2015.

31.

Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy.

De Mattia E, Cecchin E, Toffoli G.

Drug Resist Updat. 2015 May;20:39-70. doi: 10.1016/j.drup.2015.05.003. Epub 2015 May 22. Review.

PMID:
26027741
32.

MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin.

Cecchin E, Perrone G, Nobili S, Polesel J, De Mattia E, Zanusso C, Petreni P, Lonardi S, Pella N, D'Andrea M, Errante D, Rizzolio F, Mazzei T, Landini I, Mini E, Toffoli G.

Pharmacogenomics J. 2015 Jun;15(3):219-25. doi: 10.1038/tpj.2014.64. Epub 2014 Oct 21.

PMID:
25331073
33.

A pharmacogenetic survey of androgen receptor (CAG)n and (GGN)n polymorphisms in patients experiencing long term side effects after finasteride discontinuation.

Cecchin E, De Mattia E, Mazzon G, Cauci S, Trombetta C, Toffoli G.

Int J Biol Markers. 2014 Dec 9;29(4):e310-6. doi: 10.5301/jbm.5000095.

PMID:
24855036
34.

Grading the severity of obstruction in patients with chronic obstructive pulmonary disease and morbid obesity.

Barbarito N, De Mattia E.

Monaldi Arch Chest Dis. 2013 Sep-Dec;79(3-4):121-7.

35.

Pharmacogenetics of the nuclear hormone receptors: the missing link between environment and drug effects?

De Mattia E, Dreussi E, Cecchin E, Toffoli G.

Pharmacogenomics. 2013 Dec;14(16):2035-54. doi: 10.2217/pgs.13.214. Review.

PMID:
24279858
36.

Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment.

De Mattia E, Toffoli G, Polesel J, D'Andrea M, Corona G, Zagonel V, Buonadonna A, Dreussi E, Cecchin E.

Pharmacogenet Genomics. 2013 Oct;23(10):549-57. doi: 10.1097/FPC.0b013e328364b6cf.

PMID:
24018773
37.

A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen.

Cecchin E, D'Andrea M, Lonardi S, Zanusso C, Pella N, Errante D, De Mattia E, Polesel J, Innocenti F, Toffoli G.

Pharmacogenomics J. 2013 Oct;13(5):403-9. doi: 10.1038/tpj.2012.31. Epub 2012 Aug 7.

38.
39.

Which mask for noninvasive ventilation in acute respiratory failure?

Barbarito N, Vaghi A, De Mattia E.

Chest. 2011 Oct;140(4):1103. doi: 10.1378/chest.11-1223. No abstract available.

PMID:
21972397
40.

Tumor response is predicted by patient genetic profile in rectal cancer patients treated with neo-adjuvant chemo-radiotherapy.

Cecchin E, Agostini M, Pucciarelli S, De Paoli A, Canzonieri V, Sigon R, De Mattia E, Friso ML, Biason P, Visentin M, Nitti D, Toffoli G.

Pharmacogenomics J. 2011 Jun;11(3):214-26. doi: 10.1038/tpj.2010.25. Epub 2010 Apr 6.

PMID:
20368715
41.

MTHFR polymorphisms in gastric cancer and in first-degree relatives of patients with gastric cancer.

De Re V, Cannizzaro R, Canzonieri V, Cecchin E, Caggiari L, De Mattia E, Pratesi C, De Paoli P, Toffoli G.

Tumour Biol. 2010 Jan;31(1):23-32. doi: 10.1007/s13277-009-0004-1. Epub 2009 Dec 18.

42.

Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer.

Toffoli G, Cecchin E, Gasparini G, D'Andrea M, Azzarello G, Basso U, Mini E, Pessa S, De Mattia E, Lo Re G, Buonadonna A, Nobili S, De Paoli P, Innocenti F.

J Clin Oncol. 2010 Feb 10;28(5):866-71. doi: 10.1200/JCO.2009.23.6125. Epub 2009 Dec 28.

43.

Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival.

Toffoli G, Biason P, Russo A, De Mattia E, Cecchin E, Hattinger CM, Pasello M, Alberghini M, Ferrari C, Scotlandi K, Picci P, Serra M.

Clin Cancer Res. 2009 May 15;15(10):3550-6. doi: 10.1158/1078-0432.CCR-08-2249.

44.

Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan.

Cecchin E, Innocenti F, D'Andrea M, Corona G, De Mattia E, Biason P, Buonadonna A, Toffoli G.

J Clin Oncol. 2009 May 20;27(15):2457-65. doi: 10.1200/JCO.2008.19.0314. Epub 2009 Apr 13.

PMID:
19364970
45.

C677T and A1298C MTHFR polymorphisms, a challenge for antifolate and fluoropyrimidine-based therapy personalisation.

De Mattia E, Toffoli G.

Eur J Cancer. 2009 May;45(8):1333-51. doi: 10.1016/j.ejca.2008.12.004. Epub 2009 Jan 12. Review.

PMID:
19144510
46.

Pharmacogenetic relevance of MTHFR polymorphisms.

Toffoli G, De Mattia E.

Pharmacogenomics. 2008 Sep;9(9):1195-206. doi: 10.2217/14622416.9.9.1195. Review.

PMID:
18781847
47.

Pharmacology of epidermal growth factor inhibitors.

Toffoli G, De Mattia E, Cecchin E, Biason P, Masier S, Corona G.

Int J Biol Markers. 2007 Jan-Mar;22(1 Suppl 4):S24-39. Review.

PMID:
17520578
48.

Pharmacology of epidermal growth factor inhibitors.

Toffoli G, De Mattia E, Cecchin E, Biason P, Masier S, Corona G.

Int J Biol Markers. 2007 S4 - Jan-Mar;22(4):24-39. doi: 10.5301/JBM.2008.5634.

PMID:
28207111
49.

Physiological response to intrapulmonary percussive ventilation in stable COPD patients.

Nava S, Barbarito N, Piaggi G, De Mattia E, Cirio S.

Respir Med. 2006 Sep;100(9):1526-33. Epub 2006 Feb 21.

50.

Muscle retraining in ICU patients.

Cirio S, Piaggi GC, De Mattia E, Nava S.

Monaldi Arch Chest Dis. 2003 Oct-Dec;59(4):300-3. Review.

PMID:
15148840

Supplemental Content

Loading ...
Support Center